**Anexa 7B**

**II. INDICATORII DE EVALUARE UTILIZAŢI PENTRU OCUPAREA FUNCŢIILOR DIDACTICE**

(se completează tabelele la care candidaţii au subcriteriile solicitate – tabelele la care candidaţii nu au subcriteriile solicitate se vor şterge din materialul final)

**CRITERIUL I - ACTIVITATEA DIDACTICĂ**

**I.a. Elaborare materiale didactice:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **I.a.2.** | **Subcriteriu**  **Cursuri universitare (autor /coautor)** | **Puncte/unitate**  **10** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Zoltan Szabadai, Laura Sbârcea, **Lucreția** **Udrescu.** Analiza fizică și chimică a medicamentului. Editura Victor Babeș, colecția Academica, Vol.1 – 2016. ISBN 978-606-786-020-7 | | **10** |  |
| **2** | Zoltan Szabadai, Laura Sbârcea, **Lucreția Udrescu**. Analiza fizică şi chimică a medicamentului, Editura Victor Babeș, colecția Academica, Vol 2 – 2021. ISBN 978-606-786-239-3 | | **10** |  |
|  |  | | **20** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **I.a.3.** | **Subcriteriu**  **Suport de studiu pentru lucrări practice (prim autor)** | **Puncte/unitate**  **6** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Lucreția Udrescu**, Zoltan Szabadai. Analiza medicamentului. Îndrumător de lucrări practice. Editura Mirton, Timișoara, 2009, ISBN 978-973-52-0676-5 | | **6** |  |
|  |  | | **6** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **I.a.6.** | **Subcriteriu**  **Site-uri de specialitate cu scop didactic/educaţional** | **Puncte/unitate**  **5** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **https://sites.google.com/site/analizamedicamentuluiumft** | | **5** |  |
|  |  | | **5** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **I.a.7.** | **Subcriteriu**  **Teste pentru adimitere / licenţă / rezidenţiat** | **Puncte/unitate**  **4** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | [**http://www.umft.ro/licenta-2014\_329**](http://www.umft.ro/licenta-2014_329)**, Intrebari grile licenta 2014 Analiza medicamentului** | | **4** |  |
| **2** | [**http://www.umft.ro/licenta-2015\_365**](http://www.umft.ro/licenta-2015_365)**, Intrebari grile licenta 2015 Analiza medicamentului** | | **4** |  |
| **3** | **Grup de lucru Farmacie - Rezidenţiat 2011** | | **4** |  |
| **4** | **Grup de lucru Farmacie - Rezidenţiat 2012** | | **4** |  |
| **5** | **Grup de lucru Farmacie - Rezidenţiat 2013** | | **4** |  |
|  |  | | **20** |  |

**I.b. Activitatea extracuriculară cu studenţii/rezidenţii**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **I.b.5.** | **Subcriteriu**  **Organizare de Workshopuri pentru studenţi** | **Puncte/unitate**  **3** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Laura Sbarcea, **Lucreția Udrescu**. Game-Based Learning in Pharmacy Education, Conferinta TIMMED 2019 - Timisoara Medical Education Days cu tema Students as Teachers | | **3** |  |
|  |  | | **3** |  |

\*

**I.c. Voluntariat (Masterat, cursuri ECM):**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **I.c.3.** | **Subcriteriu**  **Lector cursuri practice EMC (EFC)** | **Puncte/unitate**  **2** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Controlul calității medicamentelor utilizate în managementul hipertensiunii arteriale, 22-24.03.2017 | | **2** |  |
| **2** | Metode spectrometrice de absorbție în UV-VIS și IR aplicate în controlul calității medicamentelor, 08 -10.03.2018 | | **2** |  |
| **3** | Aplicaţiile cromatografiei HPLC în controlul calităţii formelor farmaceutice, 21-23.02.2019 | | **2** |  |
| **4** | Determinarea cantitativă a substanțelor medicamentoase din diferite forme farmaceutice prin spectrofotometrie UV-VIS, 14-16.03.2019 | | **2** |  |
| **5** | Controlul calităţii medicamentelor antidiabetice innovative, 22-24.11.2019 | | **2** |  |
| **6** | Metode spectrofotometrice aplicate în analiza cantitativă a substanţelor medicamentoase din forme farmaceutice, 12-14.03.2020 | | **2** |  |
|  |  | | **12** |  |

**I.d. Lucrări de licenţă / disertaţie**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| .**Nr.**  **I.d.1.** | **Subcriteriu**  **Lucrări de licenţă/disertaţie îndrumate** | **Puncte/unitate**  **2** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **61** de lucrări de licență îndrumate | | **122** |  |
|  |  | | **122** |  |

**CRITERIUL 2- ACTIVITATEA DE CERCETARE ŞTIINŢIFICĂ**

**II.a. Grant de cercetare obținut prin competiție:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **II.a.3.** | **Subcriteriu**  **Director grant național** | **Puncte/unitate**  **30** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Complexity Science for Precision Pharmacy: Predicting Relevant Drug-Drug Interactions Using Complex Network Analysis” – HYPERION; 554PED/02.11.2020, în competiția PN-III-P2-2.1-PED-2019 (2020-2022) | | **30** |  |
|  |  | | **30** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **II.a.5.** | **Subcriteriu**  **Membru în colectiv internațional** | **Puncte/unitate**  **10** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Revolution of sleep diagnostics and personalized health care based onn digital diagnostics and therapeutics with health data integraation” – SLEEP REVOLUTION, ID 965417, în competiția europeană HORIZON 2020 (2021-2025) | | **10** |  |
| **2** | LINDE REAL Fund Project “Morpheus: a screening and monitoring system for sleep apnea syndrome” (2014-2016)  nr. 11289/ 14.10.2014 (69865 Euro) | | **10** |  |
|  |  | | **20** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **II.a.8.** | **Subcriteriu**  **Membru în echipa grant intern UMFVBT** | **Puncte/unitate**  **3** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | SYNTANTITUM III-C1-PCFI-2014/2015 “Sinteza unor compuşi cu potenţială activitate antitumorală prin reacţii de derivatizare şi caracterizarea acestora prin tehnici hifenate. Evaluarea activităţii antiangiogenice, antineoplazice şi antiinflamatoare” | | **3** |  |
|  |  | | **3** |  |

**II.b. Grant de tip workshop obținut prin competiție:**

\*

**II.c. Grant de mobilitate obținut prin competiție**:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **II.c.1.** | **Subcriteriu**  **Director grant internațional** | **Puncte/unitate**  **4** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Udrescu, L – European Respiratory Society (ERS) 2015 Gold Sponsorship – pentru participarea la *ERS International Congress 2015*, Amsterdam, 26-30 septembrie 2015 | | **4** |  |
|  |  | | **4** |  |

\*

**CRITERIUL 3 - ACTIVITATEA ȘTIINȚIFICĂ**

**III.a. Articole publicate în extenso în reviste de circulație internațională recunoscute**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.a.1.** | **Subcriteriu**  **In reviste cotate ISI ca prim autor** | **Puncte/unitate**  **15** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Udrescu L**, Bogdan P, Chiș A, Sîrbu I-O, Topîrceanu A, Văruț R-M, Udrescu M, *Uncovering new drug properties in target-based drug-drug similarity networks*, Pharmaceutics 2020, Vol. 12(9), pag. 879. | | **15** |  |
| **2** | **Udrescu L,** Sbârcea L, Topîrceanu A, Iovanovici A, Kurunczi L, Bogdan P, Udrescu M, *Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing*, Scientific Reports 2016, 6:32745. | | **15** |  |
| **3** | **Udrescu L**,Fuliaş A, Ledeţi I, Vlase G, Barvinschi P, Kurunczi L, Sbârcea L, *Host-guest System of Zofenopril and Randomly Methylated β-cyclodextrin*, Revista de Chimie 2015, Vol. 66(1), pag. 17-20. | | **15** |  |
| **4** | **Udrescu L**, Sbârcea L, Fuliaş A, Ledeţi I, Vlase G, Barvinschi P, Kurunczi L, *Physicochemical characterization of zofenopril inclusion complex with hydroxypropyl-β-cyclodextrin*, Journal of the Serbian Chemical Society 2015, Vol. 80(4), pag. 485-497. | | **15** |  |
| **5** | **Udrescu L**, Sbârcea L, Fuliaş A, Ledeţi I, Vlase G, Barvinschi P, Kurunczi L, *Physicochemical Analysis and Molecular Modeling of the Fosinopril β-Cyclodextrin Inclusion Complex*, Journal of Spectroscopy 2014, Vol. (2014):748468. | | **15** |  |
|  |  | | **75** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.a.2.** | **Subcriteriu**  **In reviste cotate ISI coautor** | **Puncte/unitate**  **10** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Groza V, Udrescu M, Bozdog A, **Udrescu L.** Drug Repurposing Using Modularity Clustering in Drug-Drug Similarity Networks Based on Drug–Gene Interactions. Pharmaceutics 2021, 13(12):2117 | | **10** |  |
| **2** | Kazakova O, Racoviceanu R, Petrova A, Mioc M, Militaru A, **Udrescu L**, Udrescu M, Voicu A, Cummings J, Robertson G, Ordway DJ, Slayden RA, Șoica C. New Investigations with Lupane Type A-Ring Azepane Triterpenoids for Antimycobacterial Drug Candidate Design. International Journal of Molecular Sciences, 2021, 22(22):12542 | | **10** |  |
| **3** | Mihaicuta S, **Udrescu L**, Udrescu M, Toth I-A, Topîrceanu A, Pleavă R, Ardelean C. Analyzing Neck Circumference as an Indicator of CPAP Treatment Response in Obstructive Sleep Apnea with Network Medicine, *Diagnostics* 2021, Vol. 11(1), pag. 86. | | **10** |  |
| **4** | Topîrceanu A, **Udrescu L**, Udrescu M, Mihăicuță S, Gender Phenotyping of Patients with Obstructive Sleep Apnea Syndrome Using a Network Science Approach, Journal of Clinical Medicine 2020, Vol. 9(12), pag. 4025. | | **10** |  |
| **5** | Rotaru LT, Varut R-M, Amzoiu E, Mormoe M, Nicolaescu O, Amzoiu MO, **Udrescu L**,Determination of the Antioxidant Capacity of Tragopogon Pratensis Species and Testing Their Pancreatic and Hepatic Regenerative Activity, *Pharmaceutical Chemistry Journal* 2020, Vol. 53(10), pag. 964–970. | | **10** |  |
| **6** | Sbârcea L, Ledeţi A, **Udrescu L**, Văruţ R-M, Barvinschi P, Vlase G, Ledeţi I, *Betulonic acid-cyclodextrins inclusion complexes*, [*Journal of Thermal Analysis and Calorimetry*](https://link.springer.com/journal/10973) 2019, Vol. 138, pag. 2787-2797 | | **10** |  |
| **7** | Topirceanu A, Udrescu A, **Udrescu L**, Ardelean C, Dan R, Reisz D, Mihaicuta S, *SAS score: Targeting high-specificity for efficient population-wide monitoring of obstructive sleep apnea*, PLoS ONE 2018, 13(9): e0202042. | | **10** |  |
| **8** | Rotaru LT, Istratoaie O, **Udrescu L**, Varut R-M, Nicolaescu O, Patruna S, Cimpoesu D, Corlade M, Mormoe M, Florescu C, Nica S, Fortofoiu M, Fortofoiu MC, *TLC, GC-MS, HPLC Analyses and Testing the Antibacterial Effect of Tragopogon pratensis and Vaccinium myrtillus*, Revista de Chimie 2018, Vol. 69(8), pag. 1939-1943. | | **10** |  |
| **9** | Mihăicuță Ș, Udrescu M, Topîrceanu A, **Udrescu L**,*Network science meets respiratory medicine for OSAS phenotyping and severity prediction*, PeerJ 2017, 5:e3289. | | **10** |  |
| **10** | SbârceaL , **Udrescu L**, Ledeţi I, Szabadai Z, Fuliaş A, Sbârcea C, β*-Cyclodextrin inclusion complexes of lisinopril and zofenopril*, Journal of Thermal Analysis and Calorimetry 2016, Vol. 123(3), pag. 2377-2390. | | **10** |  |
| **11** | Suciu L, Cristescu C, Topîrceanu A, **Udrescu L,** Udrescu M, Buda V, Tomescu MC, *Evaluation of patients diagnosed with essential arterial hypertension through network analysis*, Irish Journal of Medical Science 2016, Vol. 185(2), pag. 443-451. | | **10** |  |
| **12** | Sbârcea L, Ledeţi I, Drăgan L, Kurunczi L, Fuliaş A, **Udrescu L**,*Fosinopril sodium–hydroxypropyl-*β*-cyclodextrin inclusion complex: Thermal decomposition kinetics and compatibility studies*, Journal of Thermal Analysis and Calorimetry 2015, Vol. 120(1), pag. 981-990. | | **10** |  |
| **13** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, *Spectrophotometric method for lisinopril determination using ninhydrin*, Farmacia 2014, Vol. 62(1), pag. 107-118. | | **10** |  |
| **14** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Bojiță M, *Validated UV Spectrofotometric Method For Quantification of Zofenopril in Pharmaceutical Formulations*, Revista de Chimie 2012, Vol. 63(6), pag. 562-564. | | **10** |  |
| **15** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Sasca V, Barvinschi P, Bojiță M, *Characterization of Fosinopril Natrium-Hydroxypropyl-*β*-Cyclodextrin Inclusion Complex*, Revista de Chimie 2011, Vol. 62(3), pag. 349-351. | | **10** |  |
| **16** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, *Fosinopril-cyclodextrin inclusion complexes: phase solubility and physicochemical analysis*, Pharmazie 2011, Vol. 66(8), pag. 584-589. | | **10** |  |
| **17** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, *Thin-Layer Chromatography Analysis for Cyclodextrins Inclusions Complexes of Fosinopril and Zofenopril*, Farmacia 2010, Vol. 58(4), pag. 478–484 | | **10** |  |
|  |  | | **170** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.a.3.** | **Subcriteriu**  **In proceedings la congrese ce se găsesc pe ISI web of Knowledge/autor** | **Puncte/unitate**  **5** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Udrescu L.**, Sbârcea L. The new tale of some old drugs. Proceedings of the Romanian National Congress of Pharmacy, 17th Edition, Bucharest, Romania, Sept 26-29, 2018. Pag 234-240 | | **5** |  |
|  |  | | **5** |  |

**III.b. Articole publicate în rezumat în reviste de circulație internaționale recunoscute**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.b.1.** | **Subcriteriu**  **In reviste cotate ISI ca prim autor** | **Puncte/unitate**  **5** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Udrescu L**, Udrescu M, Mihăicuță Ș. Weighted smoking score: Measuring the benefits of quitting smoking in COPD. *European Respiratory Journal*, 2016; 48(60):OA3500 | | **5** |  |
| **2** | **Udrescu, L**, Udrescu, M, Mihăicuță, Ș. A heavy-weight combo: obstructive sleep apnea-chronic obstructive pulmonary disease overlap syndrome. *Journal of Sleep Research*, 2016, 25 (Suppl. 1):260-261, P539 | | **5** |  |
| **3** | **Udrescu L**, Udrescu M, Topîrceanu A, Mihăicuță Ș. A network-based approach to defining phenotypes in COPD. *European Respiratory Journal*, 2015; 46(9):PA3355 | | **5** |  |
| **4** | **Udrescu L**, Sbarcea L, Mihaicuta S. Cardiovascular comorbidities in chronic obstructive pulmonary disease patients. *European Respiratory Journal* 2017 50: PA3607 | | **5** |  |
|  |  | | **20** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.b.2.** | **Subcriteriu**  **In reviste cotate ISI coautor** | **Puncte/unitate**  **3** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Mihaicuta S, Udrescu L, Tiotiu A, Nadasan V, Frent SM. Occupational exposure as a predictor of asthma exacerbation – a multicenter multivariate logistical analysis. *European Respiratory Journal* 2021 58: PA1907 | | **3** |  |
| **2** | Mihaicuta S, Topirceanu A, Udrescu M, Udrescu L. A complex network approach for gender phenotyping of patients with obstructive sleep apnea syndrome. *European Respiratory Journal* 2020 56: 2517 | | **3** |  |
| **3** | Pleava R, Frent S, Ciotlos A, Marincu I, **Udrescu L**, Udrescu M, Mihaicuta S. Smoking and dyspnea severity in patients with chronic obstructive pulmonary disease. *European Respiratory Journal* 2017 50 (suppl 61): PA1258. | | **3** |  |
| **4** | Mihaicuta S, Udrescu M, Toth IA, Udrescu L, Marincu I. Statistical analysis of anthropometric differences between COPD stages 1 and 2. *European Respiratory Journal*, 2016; 48(60):PA651. | | **3** |  |
| **5** | Mihaicuta, S, Reisz, D, Dan, R, **Udrescu, L**, Topirceanu, A, Udrescu M. STOP Bang versus SASScore: prediction strategy in obstructive sleep apnea syndrome. *Journal of Sleep Research*, 2016, 25 (Suppl. 1):P816. | | **3** |  |
| **6** | Mihaicuta S, Udrescu M, Topirceanu A, Sbarcea L, **Udrescu L**. Gender Phenotyping of COPD Patients Using Complex Network Analysis. *American Journal of Respiratory and Critical Care Medicine*, 2016; 193:A3521 | | **3** |  |
| **7** | Pleava R, Frent S, Ardelean C, Reisz D, Udrescu M, **Udrescu L**, Gaita D, Dan R, Mihaicuta S. Obstructive sleep apnea syndrome and chronic kidney disease - 2 faces of metabolic disorder. *Journal of Sleep Research*, 2016, 25 (Suppl. 1):P830 | | **3** |  |
| **8** | Mihăicuță Ș, Topîrceanu A, **Udrescu L**. SAS-Score: An Innovative Prediction Model For Sleep Apnea Syndrome. *American Journal of Respiratory and Critical Care Medicine*, 2015; 191:A5617. | | **3** |  |
| **9** | Topîrceanu A, **Udrescu L**, Mihăicuță Ș. CPAP treatment response in obstructive sleep apnea using AERScore predictor. *European Respiratory Journal*, 2015; 46(9):PA2368 | | **3** |  |
|  |  | | **27** |  |

**\***

**III.c. Articole publicate în extenso în reviste naționale recunoscute**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.c.3.** | **Subcriteriu**  **In reviste cotate CNCSIS cat.B sau B+(BDI)/autor** | **Puncte/unitate**  **5** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Udrescu L**, Caunii A, Szabadai Z, Butnariu M. Brand value versus the quality of phototherapeutic products with antioxidant biocomponents from the green tea. *Studia Universitatis ”Vasile Goldiş”*, Seria Ştiinţele Vieţii, 2011; 21(3):551-556 | | **5** |  |
|  |  | | **5** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.c.4.** | **Subcriteriu**  **In reviste cotate CNCSIS cat.B sau B+(BDI)/ coautor** | **Puncte/unitate**  **3** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Sbârcea L, Drăgan L, Szabadai Z, **Udrescu L**, Bojiţă M. The determination of lisinopril based on its complexation reaction with Cu2+ using spectrophotometric methods. *Farmacia*, 2007; 2:165-170 | | **3** |  |
| **2** | Sbârcea L, **Udrescu L**, Drăgan L, Trandafirescu C, Şoica C, Bojiţă M. Thin-layer chromatographic studies of some angiotensin converting enzyme inhibitors and their inclusion complexes with β-cyclodextrin. *Studia Universitatis ”Vasile Goldiş”,* Seria Ştiinţele Vieţii, 2010; 20(2):35-38 | | **3** |  |
| **3** | Sbârcea L, **Udrescu L**, Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M. Method validation for spectrophotometric determination of lisinopril in pharmaceuticals using copper sulphate. *Clujul Medical*, 2010; 83(4):625-630 | | **3** |  |
| **4** | Caunii A, **Udrescu L**, Szabadai Z, Pribac G, Butnariu M. Total quality management of pharmaceutical preparations containing vitamin E. *Studia Universitatis ”Vasile Goldiş”*, Seria Ştiinţele Vieţii, 2012; 22(1):73-77 | | **3** |  |
| **5** | Pleavă R, Gaiţă D, Ardeleanu C, Frent S, Udrescu M, **Udrescu L**, Dan R, Reisz D, Mihăicuţă S. Obesity in association with Sleep Apnea Syndrome as predictor for coronary-vascular comorbidities. *Pneumologia* (Bucharest, Romania), 2016, 65(1):14-18 | | **3** |  |
|  |  | | **15** |  |

\*

**III.d. Monografii sau tratate publicate**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.d.3.** | **Subcriteriu**  **Tratat internațional în editură prestigioasă (membru colectiv autori)** | **Puncte/unitate**  **10** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Udrescu M, **Udrescu L.** A drug repurposing method based on drug-drug interaction networks and using energy model layouts. *Computational Methods for Drug Repurposing*, Part of the *Methods in Molecular Biology* book series, volume 1903, Humana Press, New York, NY, 2019; 185-201. | | **10** |  |
|  |  | | **10** |  |

**\***

**IIIe. Brevete, invenții, patente**

\*

**III.f. Lucrării științifice premiate**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.f.2.** | **Subcriteriu**  **Lucrării științifice premiate - la nivel naţional** | **Puncte/unitate**  **5** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | PN-III-P1-1.1- PRECISI-2021- 61864 – Premierea rezultatelor cercetării – *zona galbenă* – pentru articolul: S. Mihaicuta, **L. Udrescu**, M. Udrescu, I.-A. Toth, A. Topîrceanu, R. Pleavă, C. Ardelean, Analyzing Neck Circumference as an Indicator of CPAP Treatment Response in Obstructive Sleep Apnea with Network Medicine. *Diagnostics* 2021 | | **5** |  |
| **2** | PN-III-P1-1.1- PRECISI-2021- 53403 – Premierea rezultatelor cercetării – *zona roșie* – pentru articolul: A. Topîrceanu, **L. Udrescu**, M. Udrescu, S. Mihaicuta, Gender Phenotyping of Patients with Obstructive Sleep Apnea Syndrome Using a Network Science Approach. *Journal of Clinical Medicine* 2020 | | **5** |  |
| **3** | PN-III-P1-1.1-PRECISI-2020-51588 – Premierea rezultatelor cercetării – *zona roșie* – pentru articolul: **L. Udrescu**, A. Chis, I.O. Sîrbu, A. Topîrceanu, R. Văruț, M. Udrescu, Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks. *Pharmaceutics* 2020 | | **5** |  |
| **4** | PN-III-P1-1.1-PRECISI-2020-50082 – Premierea rezultatelor cercetării – *zona galbenă* – pentru articolul: L. Sbârcea, A. Ledeţi, **L. Udrescu**, R.-M. Văruţ, P. Barvinschi, G. Vlase, I. Ledeţi, Betulonic acid-cyclodextrins inclusion complexes, *Journal of Thermal Analysis And Calorimetry*, 2019 | | **5** |  |
| **5** | PN-III-P1-1.1- PRECISI-2019- 31356 – Premierea rezultatelor cercetării – *zona roșie* – pentru articolul: A. Topirceanu, M. Udrescu, **L. Udrescu**, C. Ardelean, R. Dan, D. Reisz, S. Mihaicuta, SAS score: Targeting high-specificity for efficient population-wide monitoring of obstructive sleep apnea. *PLoS One* 2018 | | **5** |  |
| **6** | PN-III-P1-1.1-PRECISI-2017-18749 – Premierea rezultatelor cercetării – *zona galbenă* – pentru articolul: S. Mihaicuta, M. Udrescu, A. Topirceanu, **L. Udrescu**. Network science meets respiratory medicine for OSAS phenotyping and severity prediction. *PeerJ* 2017 | | **5** |  |
| **7** | UEFISCDI PNCDI III – Premierea rezultatelor cercetării – *zona roșie* – pentru articolul: **L. Udrescu**, L. Sbârcea, A. Topîrceanu, A. Iovanovici, L. Kurunczi, P. Bogdan, M. Udrescu. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing. *Scientific Reports* 2016 | | **5** |  |
|  |  | | **35** |  |

**III.g. Participare la manifestări științifice internaționale**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.g.2.** | **Subcriteriu**  **Comunicări orale prim autor** | **Puncte/unitate**  **6** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Udrescu L, Udrescu M, Topîrceanu A, Mihaicuta S. A network-based approach to defining phenotypes in COPD. ERS International Congress, Amsterdam, 26-30 septembrie 2015 | | **6** |  |
| **2** | **Udrescu L**, Udrescu M, Mihaicuta S. Weighted smoking score: Measuring the benefits of quitting smoking in COPD. ERS International Congress, Londra, 3-7 septembrie 2016 | | **6** |  |
|  |  | | **12** |  |

**\***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.g.4.** | **Subcriteriu**  **Poster** | **Puncte/unitate**  **1** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1** | **Udrescu L**, Sbarcea L, Mihaicuta S. Cardiovascular comorbidities in chronic obstructive pulmonary disease patients. *ERS International Congress*, Milano, Italia, 9-13 septembrie 2017 | | **1** |  |
| **2** | **Udrescu L**, Fuliaş A, Ledeţi I, Drăgan L, Suciu L, Olariu I, Kurunczi L, Sbârcea L. The effect of water and ethanol on the inclusion complexation of fosinopril sodium and beta-cyclodextrin. 17th International Cyclodextrin Symposium, Saarbrucken, 29 – 31 mai 2014 | | **1** |  |
|  |  | | **2** |  |

**III.h. Participare la manifestări științifice naţionale cu participare internațională**

\*

**III.i. Participare la manifestări științifice naționale**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.i.2.** | **Subcriteriu**  **Comunicări orale prim autor** | **Puncte/unitate**  **2** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Udrescu L**, Sbarcea L. The new tale of some old drugs. Congresul National de Farmacie din Romania, Editia a XVII-a, Bucuresti, 26-29 septembrie 2018 | | **2** |  |
|  |  | | **2** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **III.i.3.** | **Subcriteriu**  **Comunicări orale coautor** | **Puncte/unitate**  **1** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Suciu L, Chiș AR, Sbarcea L, Topîrceanu A, Udrescu M, Iovanovici A, Ardelean S, **Udrescu L**. Comparison of drug interactions from international databases. Congresul National de Farmacie din Romania, Oradea, Editia a XVIII-a, 15-17 septembrie 2021 (online) | | **1** |  |
|  |  | | **1** |  |

**\***

**CRITERIUL 4 - PRESTIGIUL PROFESIONAL**

**IV.a. Citare de lucrări în sistemul ISI ( se scrie și numele revistei / tratate / monografii)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **IV.a.1.** | **Subcriteriu**  **Citări în reviste cotate ISI** | **Puncte/unitate**  **4** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Udrescu L,** Sbârcea L, Topîrceanu A, Iovanovici A, Kurunczi L, Bogdan P, Udrescu M, *Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing*, Scientific Reports 2016, 6:32745 – citat în *Pharmaceutics* 2021 – Avram S. et al. [3D-ALMOND-QSAR Models to Predict the Antidepressant Effect of Some Natural Compounds](https://www-webofscience-com.am.e-nformation.ro/wos/woscc/full-record/WOS:000701459400001)*Briefings in Bioinformatics* 2021 – Badkas A. et al. Topological network measures for drug repositioning*Pharmaceutics* 2021 –Groza V et al. Drug Repurposing Using Modularity Clustering in Drug-Drug Similarity Networks Based on Drug-Gene Interactions*IEEE-ACM Transactions on Computational Biology and Bioinformatics* 2021 – Sadeghi SS, Keyvanpour, MR. An Analytical Review of Computational Drug Repurposing*Diagnostics* 2021 – Mihaicuta S. et al. Analyzing Neck Circumference as an Indicator of CPAP Treatment Response in Obstructive Sleep Apnea with Network Medicine*Journal of Clinical Medicine* 2020 – Topirceanu A. et al. Gender Phenotyping of Patients with Obstructive Sleep Apnea Syndrome Using a Network Science Approach*Pharmaceutics* 2020 – Udrescu L. et al. Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks*International Journal of Medical Informatics* 2020 – Shirazi S. et al. A new application of community detection for identifying the real specialty of physicians*Biochimica et Biophysica Acta-Gene Regulatory Mechanisms* 2020 – Conte F. et al. A paradigm shift in medicine: A comprehensive review of network-based approaches*Frontiers in Applied Mathematics and Statistics* 2020 – Znaidi M.R. et al. Identifying Arguments of Space-Time Fractional Diffusion: Data-Driven Approach*Journal of King Saud University Science* 2020 – Zainab B. et al. Repositioning of strongly integrated drugs against achromatopsia (CNGB3)*IEEE International Symposium on Circuits And Systems* (ISCAS) 2020 – Nazarian S., Bogdan P. S(4)oC: A Self-optimizing, Self-adapting Secure System-on-Chip Design Framework to Tackle Unknown Threats - A Network Theoretic, Learning Approach*Computational and Structural Biotechnology Journal* 2020 – Zhou YT, Lauschke VM. Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition*Pharmacological Reviews* 2020 – Hendrickx JO et al. High-dimensionality Data Analysis of Pharmacological Systems Associated with Complex Diseases*Frontiers in Physiology* 2019 – Bogdan P. Taming the Unknown Unknowns in Complex Systems: Challenges and Opportunities for Modeling, Analysis and Control of Complex (Biological) Collectives*Plos One* 2019 – He S. A new grid- and modularity-based layout algorithm for complex biological networks*Scientific Reports* 2019 – Sia J. Ollivier-Ricci Curvature-Based Method to Community Detection in Complex Networks*Briefings in Bioinformatics* 2019 – Zhu YJ et al. Drug knowledge bases and their applications in biomedical informatics research*Journal of Cellular and Molecular Medicine* 2019 – Seclaman E. et al. MicroRNAs mediate liver transcriptome changes upon soy diet intervention in miceCOMPUTATIONAL METHODS FOR DRUG REPURPOSING 2019 – Zheng S et al. A Computational Bipartite Graph-Based Drug Repurposing MethodCOMPUTATIONAL METHODS FOR DRUG REPURPOSING 2019 – Udrescu M, Udrescu L. A Drug Repurposing Method Based on Drug-Drug Interaction Networks and Using Energy Model Layouts*Future Generation Computer Systems-The International Journal of E-science* 2018 – Gomez-Romero J et al. Visualizing large knowledge graphs: A performance analysis*Computational Biology and Chemistry* 2018 – Munir A et al. Clustering based drug-drug interaction networks for possible repositioning of drugs against EGFR mutations: Clustering based DDI networks for EGFR mutations*Knowledge and Information Systems* 2018 – Bu Z. et al. GLEAM: a graph clustering framework based on potential game optimization for large-scale social networks*Plos One* 2018 – Kastrin A et al. Predicting potential drug-drug interactions on topological and semantic similarity features using statistical learningSWARM INTELLIGENCE 2018 – Udrescu M, Lihu A. Agreeing to disagree: synergies between particle swarm optimization and complex networksPROCEEDINGS OF THE ROMANIAN NATIONAL CONGRESS OF PHARMACY 2018 – Udrescu L, Sbarcea L. The new tale of some old drugsPACIFIC SYMPOSIUM ON BIOCOMPUTING 2018 – Xu JL, et al. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies*Complexity* 2018 – Topirceanu A. Competition-Based Benchmarking of Influence Ranking Methods in Social Networks*IEEE Access* 2018 – Cheng X et al. Open Knowledge Accessing Method in IoT-Based Hospital Information System for Medical Record Enrichment*PeerJ* 2017 – Mihaicuta S et al. Network science meets respiratory medicine for OSAS phenotyping and severity prediction | | **124** |  |
| **2** | **Udrescu L,** Sbârcea L, Fuliaş A, Ledeţi I, Vlase G, Barvinschi P, Kurunczi L, Physicochemical Analysis and Molecular Modeling of the Fosinopril β-Cyclodextrin Inclusion Complex, Journal of Spectroscopy 2014, Vol. (2014):748468 – citat în:   1. *Journal of Inclusion Phenomena and Macrocyclic Chemistry* 2022 – HM Hnin at al. Angiotensin converting enzyme inhibitors/cyclodextrin inclusion complexes: solution and solid-state characterizations and their thermal stability 2. *Separation and Purification Technology* 2021 – Minhas MA et al. Selective and efficient extraction of cationic dyes from industrial effluents through polymer inclusion membrane 3. *Molecules* 2021 - Sbarcea L et al. Risperidone/Randomly Methylated beta-Cyclodextrin Inclusion Complex-Compatibility Study with Pharmaceutical Excipients 4. *Pharmaceutics* 2020 – Udrescu L. et al.Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks 5. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Physicochemical characterization and molecular modeling study of host-guest systems of aripiprazole and functionalized cyclodextrins 6. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Compatibility studies with pharmaceutical excipients for aripiprazole-heptakis (2,6-di-O-methyl)-beta-cyclodextrin supramolecular adduct 7. *Journal of Molecular Structure* 2020 – Hui BY et al. A comprehensive molecular insight into host-guest interaction of Phenanthrene with native and ionic liquid modified beta-cyclodextrins: Preparation and characterization in aqueous medium and solid state 8. *Journal of Organic Chemistry* 2019 – Kasprzak A et al. Supramolecular Interactions between beta-Cyclodextrin and the Nucleobase Derivatives of Ferrocene 9. *Journal of Thermal Analysis and Calorimetry* 2019 – Sbarcea L. et al. Betulonic acid-cyclodextrins inclusion complexes 10. *Industrial Crops and Products* 2019 – Yuan C et al. Physicochemical characterization and antibacterial activity assessment of lavender essential oil encapsulated in hydroxypropyl-beta-cyclodextrin 11. *Acta Scientiarum-Technology* 2019 – Valarini O. et al. Complexation and physicochemical analysis of hydrophobic molecules of methyl jasmonate with Hydroxypropyl-beta-Cyclodextrin 12. *Journal of Supercritical Fluids* 2017 – Valarini O. et al. Formation of inclusion compounds of (+)catechin with beta-cyclodextrin in different complexation media: Spectral, thermal and antioxidant properties 13. *Journal of Thermal Analysis and Calorimetry* 2016 – Sbarcea L. et al. beta-Cyclodextrin inclusion complexes of lisinopril and zofenopril | | **52** |  |
| **3** | Mihăicuță Ș, Udrescu M, Topîrceanu A, **Udrescu L**,*Network science meets respiratory medicine for OSAS phenotyping and severity prediction*, PeerJ 2017, 5:e3289 – citat în:   1. *IEEE Sensors Journ*al 2021 – Jablonski I. et al. The Complexity and Variability Mapping for Prediction and Explainability of the Sleep Apnea Syndrome 2. *Frontiers in Physiology* 2021 – Barajas-Martinez A et al. Sex Differences in the Physiological Network of Healthy Young Subjects 3. *Frontiers in Cardiovascular Medicine* 2021 – Chen J et al. An Update on Obstructive Sleep Apnea for Atherosclerosis: Mechanism, Diagnosis, and Treatment 4. *Medicina-Lithuania* 2021 – Charciunaite, K et al. Evaluation of Obstructive Sleep Apnea Phenotypes Treatment Effectiveness 5. *Frontiers in Physiology* 2021 – Barajas-Martinez A et al. Physiological Network From Anthropometric and Blood Test Biomarkers 6. *Diagnostics* 2021 – Mihaicuta S et al. Analyzing Neck Circumference as an Indicator of CPAP Treatment Response in Obstructive Sleep Apnea with Network Medicine 7. *Journal of Clinical Medicine* 2020 – Topirceanu A. et al. Gender Phenotyping of Patients with Obstructive Sleep Apnea Syndrome Using a Network Science Approach 8. *Respirology* 2020 - Mansfield, DR. Obstructive sleep apnoea phenotypes: The many faces of a public health monolith 9. *Archivos de Bronconeumologia* 2020 – Silveira MG, Lloberes P. Cluster Analysis to Identify Apnea-Hypopnea Syndrome Phenotypes: Where Are We Heading? 10. *Frontiers in Physiology* 2020 – Gabryelska, A et al. HIF-1 alpha as a Mediator of Insulin Resistance, T2DM, and Its Complications: Potential Links With Obstructive Sleep Apnea 11. *Medicina-Lithuania* 2019 – Ardelean CL et al. Particularities of Older Patients with Obstructive Sleep Apnea and Heart Failure with Mid-Range Ejection Fraction 12. *Chest* 2019 – Suen C et al. Sleep Study and Oximetry Parameters for Predicting Postoperative Complications in Patients With OSA 13. *Chaos Solitons & Fractals* 2019 – Zanin M et al. Characterising obstructive sleep apnea patients through complex networks 14. *Plos One* 2018 – Topirceanu A et al. SAS score: Targeting high-specificity for efficient population-wide monitoring of obstructive sleep apnea 15. *Experimental and Therapeutic Medicine* 2018 – Zhang JD et al. Correlation between coronary artery disease and obstructive sleep apnea syndrome and analysis of risk factors 16. 27. PROCEEDINGS OF THE ROMANIAN NATIONAL CONGRESS OF PHARMACY 2018 – Udrescu L, Sbarcea L. The new tale of some old drugs 17. *European Respiratory Review* 2017 – Bonsignore, MR et al. Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment | | **68** |  |
| **4** | Sbârcea L, **Udrescu L**, Ledeţi I, Szabadai Z, Fuliaş A, Sbârcea C, β-Cyclodextrin inclusion complexes of lisinopril and zofenopril, Journal of Thermal Analysis and Calorimetry 2016, Vol. 123(3), pag. 2377-2390 – citat în:   1. *Molecules* 2020 – Sbarcea L. et al. Encapsulation of Risperidone by Methylated beta-Cyclodextrins: Physicochemical and Molecular Modeling Studies 2. *Molecules* 2020 – Marques CSF et al. beta-Cyclodextrin/Isopentyl Caffeate Inclusion Complex: Synthesis, Characterization and Antileishmanial Activity 3. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Physicochemical characterization and molecular modeling study of host-guest systems of aripiprazole and functionalized cyclodextrins 4. *Journal of Thermal Analysis and Calorimetry* 2020 – Circioban D et al. Instrumental analysis and molecular modelling of inclusion complexes containing artesunate 5. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Compatibility studies with pharmaceutical excipients for aripiprazole-heptakis (2,6-di-O-methyl)-beta-cyclodextrin supramolecular adduct 6. *Journal of Thermal Analysis and Calorimetry* 2020 – Circioban D et al. Preparation, physicochemical characterization and biological activity evaluation of some inclusion complexes containing artesunate 7. *Journal of Inclusion Phenomena and Macrocyclic Chemistry* 2020 – Stoicescu CS et al. Inclusion complexes of some thiourea derivatives in cyclodextrins 8. *Journal of Thermal Analysis and Calorimetry* 2019 – Sbarcea L et al. Betulonic acid-cyclodextrins inclusion complexes 9. *Journal of Thermal Analysis and Calorimetry* 2019 – Ohata T et al. Effect of solution pH on complex formation between epi-type catechin and -cyclodextrin 10. CYCLODEXTRIN FUNDAMENTALS, REACTIVITY AND ANALYSIS 2018 – Hadaruga NG et al. Thermal Analyses of Cyclodextrin Complexes 11. *Journal of Thermal Analysis and Calorimetry* 2017 – Jacimovic, ZK et al. Pyrazole-type complexes with Ni(II) and Cu(II) Solvent exchange reactions in coordination compounds 12. *Journal of Thermal Analysis and Calorimetry* 2017 – Dhall M et al. Thermal and other analytical studies on bifenthrin urea co-inclusion complex A human-guarded insecticide formulation | | **48** |  |
| **5** | Sbârcea L, Ledeţi I, Drăgan L, Kurunczi L, Fuliaş A, **Udrescu L**,*Fosinopril sodium–hydroxypropyl-*β*-cyclodextrin inclusion complex: Thermal decomposition kinetics and compatibility studies*, Journal of Thermal Analysis and Calorimetry 2015, Vol. 120(1), pag. 981-990 – citat în:   1. *Molecules* 2021 – Sbarcea L et al. Risperidone/Randomly Methylated beta-Cyclodextrin Inclusion Complex-Compatibility Study with Pharmaceutical Excipients 2. *Molecules* 2020 – Sbarcea L et al. Encapsulation of Risperidone by Methylated beta-Cyclodextrins: Physicochemical and Molecular Modeling Studies 3. *Flavour and Fragrance Journal* 2020 – Hu J et al. Comparative study on the effect of two drying methods on the guest encapsulation behavior of osmanthus flavor-2-hydroxypropyl-beta-cyclodextrin inclusion complex 4. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Physicochemical characterization and molecular modeling study of host-guest systems of aripiprazole and functionalized cyclodextrins 5. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Compatibility studies with pharmaceutical excipients for aripiprazole-heptakis (2,6-di-O-methyl)-beta-cyclodextrin supramolecular adduct 6. *Journal of Thermal Analysis and Calorimetry* 2020 – Circioban D et al. Preparation, physicochemical characterization and biological activity evaluation of some inclusion complexes containing artesunate 7. *Journal of Thermal Analysis and Calorimetry* 2020 – Rojek B et al. Compatibility study of theophylline with excipients using thermogravimetry supported by kinetic analysis 8. *Journal of Thermal Analysis and Calorimetry* 2019 – Sbarcea L. et al. Betulonic acid-cyclodextrins inclusion complexes 9. *International Journal of Endocrinology* 2019 –Farhadi, SAS and Dizaye, KF. Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction 10. CYCLODEXTRIN FUNDAMENTALS, REACTIVITY AND ANALYSIS 2018 – Hadaruga NG et al. Thermal Analyses of Cyclodextrin Complexes 11. *Journal of Thermal Analysis and Calorimetry* 2016 – Sbarcea L. et al. beta-Cyclodextrin inclusion complexes of lisinopril and zofenopril | | **44** |  |
| **6** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, *Fosinopril-cyclodextrin inclusion complexes: phase solubility and physicochemical analysis*, Pharmazie 2011, Vol. 66(8), pag. 584-589 – citat în:   1. *Separation and Purification Technology* 2021 – Minhas MA et al. Selective and efficient extraction of cationic dyes from industrial effluents through polymer inclusion membrane 2. *Molecules* 2020 – Sbarcea L et al. Encapsulation of Risperidone by Methylated beta-Cyclodextrins: Physicochemical and Molecular Modeling Studies 3. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Physicochemical characterization and molecular modeling study of host-guest systems of aripiprazole and functionalized cyclodextrins 4. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Compatibility studies with pharmaceutical excipients for aripiprazole-heptakis (2,6-di-O-methyl)-beta-cyclodextrin supramolecular adduct 5. *International Journal of Molecular Sciences* 2020 – Han DX et al. Solubility Enhancement of Myricetin by Inclusion Complexation with Heptakis-O-(2-Hydroxypropyl)-beta-Cyclodextrin: A Joint Experimental and Theoretical Study 6. *Journal of Thermal Analysis and Calorimetry* 2019 – Sbarcea L. et al. Betulonic acid-cyclodextrins inclusion complexes 7. *Journal of Thermal Analysis and Calorimetry* 2016 – Sbarcea L. et al. beta-Cyclodextrin inclusion complexes of lisinopril and zofenopril 8. *Journal of Thermal Analysis and Calorimetry* 2015 – Sbarcea L. et al. Fosinopril sodium-hydroxypropyl-beta-cyclodextrin inclusion complex 9. *Journal of the Serbian Chemical Society* 2015 – Udrescu L. et al. Physicochemical characterization of zofenopril inclusion complex with 2-hydroxypropyl-beta-cyclodextrin 10. *Journal of Spectroscopy* 2014 - Physicochemical Analysis and Molecular Modeling of the Fosinopril beta-Cyclodextrin Inclusion Complex | | **40** |  |
| **7** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Sasca V, Barvinschi P, Bojiță M, *Characterization of Fosinopril Natrium-Hydroxypropyl-*β*-Cyclodextrin Inclusion Complex*, Revista de Chimie 2011, Vol. 62(3), pag. 349-351 – citat în:   1. *Molecules* 2021 – Sbarcea L et al. Risperidone/Randomly Methylated beta-Cyclodextrin Inclusion Complex-Compatibility Study with Pharmaceutical Excipients 2. *International Journal of Infectious Diseases* 2020 – Marian E et al. Antimicrobial activity of fusidic acid inclusion complexes 3. *Molecules* 2020 – Sbarcea L et al. Encapsulation of Risperidone by Methylated beta-Cyclodextrins: Physicochemical and Molecular Modeling Studies 4. *Arabian Journal of Chemistry* 2020 – Marian E. et al. Synthesis, characterization of inclusion compounds of amygdalin with beta-cyclodextrin and sod-like activity and cytotoxicity on hela tumor cells 5. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Physicochemical characterization and molecular modeling study of host-guest systems of aripiprazole and functionalized cyclodextrins 6. *Journal of Thermal Analysis and Calorimetry* 2019 – Sbarcea L. et al. Betulonic acid-cyclodextrins inclusion complexes 7. *Journal of Thermal Analysis and Calorimetry* 2015 – Sbarcea L. et al. Fosinopril sodium-hydroxypropyl-beta-cyclodextrin inclusion complex 8. *Revista de Chimie* 2015 – Udrescu L. et al. Host-guest System of Zofenopril and Randomly Methylated beta-cyclodextrin Preparation, characterization and solubility 9. *Journal of Spectroscopy* 2014 – Physicochemical Analysis and Molecular Modeling of the Fosinopril beta-Cyclodextrin Inclusion Complex 10. *Revista de Chimie* 2011 – Marian E. et al. Inclusion Compounds of Erythromycin with beta-cyclodextrin | | **40** |  |
| **8** | Sbârcea L, Ledeţi A, **Udrescu L**, Văruţ R-M, Barvinschi P, Vlase G, Ledeţi I, *Betulonic acid-cyclodextrins inclusion complexes*, [Journal of Thermal Analysis and Calorimetry](https://link.springer.com/journal/10973) 2019, Vol. 138, pag. 2787-2797 – citat în:   1. *Separation and Purification Technology* 2021 – Minhas MA et al. Selective and efficient extraction of cationic dyes from industrial effluents through polymer inclusion membrane 2. *Reactive & Functional Polymers* 2021 – Babaev M et al. Nanoparticles of self-organizing ionic complexes based on a copolymer of N,N '-diallyl-N,N '-dimethylammonium chloride with N-vinylpyrrolidone modified by betulonic acid 3. *International Journal of Molecular Science*S 2021 – Lombrea A et al. Anticancer Potential of Betulonic Acid Derivatives 4. *Molecules* 2021 – Sbarcea L et al. Risperidone/Randomly Methylated beta-Cyclodextrin Inclusion Complex-Compatibility Study with Pharmaceutical Excipients 5. *Journal of Thermal Analysis and Calorimetry* 2021 – Gatiatulin, AK et al. Guest exchange in anhydrous inclusion compounds of alpha-cyclodextrin and its amorphization 6. *Molecules* 2020 – Sbarcea L et al. Encapsulation of Risperidone by Methylated beta-Cyclodextrins: Physicochemical and Molecular Modeling Studies 7. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Physicochemical characterization and molecular modeling study of host-guest systems of aripiprazole and functionalized cyclodextrins 8. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Compatibility studies with pharmaceutical excipients for aripiprazole-heptakis (2,6-di-O-methyl)-beta-cyclodextrin supramolecular adduct | | **32** |  |
| **9** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, *Thin-Layer Chromatography Analysis for Cyclodextrins Inclusions Complexes of Fosinopril and Zofenopril*, Farmacia 2010, Vol. 58(4), pag. 478–484 – citat în:   1. RSC ADVANCES 2019 - Alshaer, W et al. Encapsulation of echinomycin in cyclodextrin inclusion complexes into liposomes: in vitro anti-proliferative and anti-invasive activity in glioblastoma 2. *Revista de Chimie* 2018 – Rotaru LT et al. TLC, GC-MS, HPLC Analyses and Testing the Antibacterial Effect of Tragopogon pratensis and Vaccinium myrtillus 3. *Spectrochimica Acta Part A-Molecular and Biomolecular Spectroscopy* 2015 - Stolarczyk, M et al. Derivative spectrophotometric method for simultaneous determination of zofenopril and fluvastatin in mixtures and pharmaceutical dosage forms 4. *Journal of the Serbian Chemical Society* 2015 – Udrescu L. et al. Physicochemical characterization of zofenopril inclusion complex with 2-hydroxypropyl-beta-cyclodextrin 5. *Revista de Chimie* 2015 – Udrescu L. et al. Host - guest System of Zofenopril and Randomly Methylated beta - cyclodextrin Preparation, characterization and solubility 6. *Journal of Spectroscopy* 2014 - Physicochemical Analysis and Molecular Modeling of the Fosinopril beta-Cyclodextrin Inclusion Complex 7. *Farmacia* 2012 – Gavriloaia MR et al. In Vitro Evaluation of Diffusion and Rheological Profiles for Dexamethasone Inclusion Complexes with Beta-Cyclodextrin or Hydroxypropyl Beta-Cyclodextrin 8. *Farmacia* 2011 – Ebrahim ZAJ et al. HPTLC Method for the Assay of Tramadol and Pentazocine from Mixtures | | **32** |  |
| **10** | Topirceanu A, Udrescu A, **Udrescu L**, Ardelean C, Dan R, Reisz D, Mihaicuta S, *SAS score: Targeting high-specificity for efficient population-wide monitoring of obstructive sleep apnea*, PLoS ONE 2018, 13(9): e0202042 – citat în:   1. Knowledge-Based and Intelligent Information & Engineering Systems (KSE 2021) – Topirceanu A. Immunization using a heterogeneous geo-spatial population model: A qualitative perspective on COVID-19 vaccination strategies 2. *Diagnostics* 2021 – Mihaicuta S. et al. Analyzing Neck Circumference as an Indicator of CPAP Treatment Response in Obstructive Sleep Apnea with Network Medicine 3. *Journal of Clinical Medicine* 2020 – Topirceanu A et al.Gender Phenotyping of Patients with Obstructive Sleep Apnea Syndrome Using a Network Science Approach 4. *Sleep and Breathing* 2021 – Zhang ZH et al. Effects of age and sex on the performance of the NoSAS score as a screening tool for obstructive sleep apnea: a hospital-based retrospective study in China 5. *Sleep Medicine* 2020 - Mashaqi, S et al. Combined nocturnal pulse oximetry and questionnaire-based obstructive sleep apnea screening - A cohort study 6. *International Journal of Clinical and Experimental Medicine* 2020 – Liu YL et al. Influence of seamless nursing on the stress state of patients undergoing transurethral prostate resection 7. *Medicina-Lithuania* 2019 – Ardelean CL et al. Particularities of Older Patients with Obstructive Sleep Apnea and Heart Failure with Mid-Range Ejection Fraction | | **28** |  |
| **11** | Rotaru LT, Istratoaie O, **Udrescu L**, Varut R-M, Nicolaescu O, Patruna S, Cimpoesu D, Corlade M, Mormoe M, Florescu C, Nica S, Fortofoiu M, Fortofoiu MC, *TLC, GC-MS, HPLC Analyses and Testing the Antibacterial Effect of Tragopogon pratensis and Vaccinium myrtillus*, Revista de Chimie 2018, Vol. 69(8), pag. 1939-1943 – citat in:   1. *Journal of Science and Arts* 2020 – Rotaru LT et al. Antibacterial Activity of Fresh Onion and Garlic Juices 2. *Journal of Science and Arts* 2020 – Varut RM et al. The Chemisorption-Release and Antibacterial Potential Studies of Gentamicin from Hydroxyapatite-Based Implants 3. *Journal of Science and Arts* 2020 – Rotaru LT et al. Carduus Acanthoides Folium Tincture: Chemical Composition, Antibacterial Activity and Synergistic / Antagonist Effect in Combination with Antibiotics 4. *Journal of Science and Arts* 2020 – Rotaru LT et al. Antibacterial Property and Molecular Docking Studies of Tamarix Ramosissima Plant Extract 5. *Journal of Science and Arts* 2020 – Florescu C et al. Correlation of Polyphenolic Compounds Structural Properties with Their Antioxidant Capacity 6. *Revista de Chimie* 2019 – Rotaru LT et al. Correlation of the Theoretical Study with the Experimental Determination of the Antibacterial Effect of Vaccinium myrtillus folium (VM-f) Plant Extract 7. *Revista de Chimie* 2019 – Nicolaescu O et al. Determination of the Polyphenolic Content of Dorycnium herbaceum Plant Extract and Testing in vivo Antioxidant Effect, Comparative with Bilberry | | **28** |  |
| **12** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, *Spectrophotometric method for lisinopril determination using ninhydrin*, Farmacia 2014, Vol. 62(1), pag. 107-118 – citat în:   1. *Pharmacia* 2021 - Shulyak, N et al. Spectrophotometric methods for the determination of lisinopril in medicines 2. *Pakistan Journal of Analytical & Environmental Chemistry* 2021 – Zounr ZA et al. Determination of Lisinopril in Pure and Tablet form by Using 2-Hydroxynaphthaldehyde as Derivatizing Reagent 3. *Oriental Journal of Chemistry* 2019 - Ninhydrin Based Visible Spectrophotometric Determination of Gemigliptin 4. *Farmacia* 2015 – Constantinescu IC et al. Development of a Spectrophotometric Method for Determination of Fluoxetine Hydrochloride in Bulk and Pharmaceutical Dosage Forms 5. *Farmacia* 2015 – Olteanu AA et al. Investigation of Cyclodextrin Based Nanosponges Complexes with Angiotensin I Converting Enzyme Inhibitors (Enalapril, Captopril, Cilazapril) 6. *Revue Roumaine de Chimie* 2015 – Yakar C et al. Recent Analytical Applications on Antihypertensive Drugs 7. *Farmacia* 2015 – Farcas A et al. The Current Insight on Dual Renin-Angiotensin System Blockade: A Data Review with a Focus on Safety | | **28** |  |
| **13** | Sbârcea L, **Udrescu L**, Drăgan L, Trandafirescu C, Bojiță M, *Validated UV Spectrofotometric Method For Quantification of Zofenopril in Pharmaceutical Formulations*, Revista de Chimie 2012, Vol. 63(6), pag. 562-564 – citat în:   1. *Revista de Chimie* 2017 – Bratu MM et al. Electrophoretic Method For Edible Eggs Species Identification 2. *Journal of Thermal Analysis and Calorimetry* 2016 – Sbarcea L. et al. beta-Cyclodextrin inclusion complexes of lisinopril and zofenopril 3. *Revista de Chimie* 2015 – Birghila S et al. Spectrophotometric Method for the Determination of Total Proteins in Egg White Samples 4. *Revista de Chimie* 2015 – Udrescu L. et al. Host - guest System of Zofenopril and Randomly Methylated beta - cyclodextrin Preparation, characterization and solubility 5. *Journal of Pharmaceutical and Biomedical Analysis* 2014 – Ramesh T et al. LC-MS/MS characterization of forced degradation products of zofenopril 6. *Revista de Chimie* 2013 – Gherman S et al. Spectrophotometric Determination of Enalapril Using Tropeolin 00 7. *Revista de Chimie* 2013 – Jung A et al. Gas-chromatographic Method for Volatile Congeners in Alcoholic Beverages Analysis | | **28** |  |
| **14** | **Udrescu L**, Sbârcea L, Fuliaş A, Ledeţi I, Vlase G, Barvinschi P, Kurunczi L, *Physicochemical characterization of zofenopril inclusion complex with hydroxypropyl-β-cyclodextrin*, Journal of the Serbian Chemical Society 2015, Vol. 80(4), pag. 485-497 – citat în:   1. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Compatibility studies with pharmaceutical excipients for aripiprazole-heptakis (2,6-di-O-methyl)-beta-cyclodextrin supramolecular adduct 2. *International Journal of Molecular Sciences* 2020 – Han DX et al. Solubility Enhancement of Myricetin by Inclusion Complexation with Heptakis-O-(2-Hydroxypropyl)-beta-Cyclodextrin: A Joint Experimental and Theoretical Study 3. *Journal of Drug Delivery Science and Technology* 2019 – Prajapat MD et al. Liquisolid: A promising technique to improve dissolution efficiency and bioavailability of poorly water soluble nimodipine 4. *Journal of Hazardous Materials* 2019 – Moon Y et al. Organophosphorus hydrolase-poly-beta-cyclodextrin as a stable self-decontaminating bio-catalytic material for sorption and degradation of organophosphate pesticide 5. *Journal of Pharmaceutical Analysis* 2016 – Sapte S, Pore Y. Inclusion complexes of cefuroxime axetil with beta-cyclodextrin: Physicochemical characterization, molecular modeling and effect of L-arginine on complexation 6. *Journal of Thermal Analysis and Calorimetry* 2016 – Sbarcea L. et al. beta-Cyclodextrin inclusion complexes of lisinopril and zofenopril | | **24** |  |
| **15** | **Udrescu L**, Bogdan P, Chiș A, Sîrbu I-O, Topîrceanu A, Văruț R-M, Udrescu M, *Uncovering new drug properties in target-based drug-drug similarity networks*, Pharmaceutics 2020, Vol. 12(9), pag. 879 – citat în:   1. *Pharmaceutics* 2021 – Groza V et al. Drug Repurposing Using Modularity Clustering in Drug-Drug Similarity Networks Based on Drug-Gene Interactions 2. *International Journal of Molecular Sciences* 2021 – Kazaova O et al. New Investigations with Lupane Type A-Ring Azepane Triterpenoids for Antimycobacterial Drug Candidate Design 3. *Pharmaceutics* 2021 – Avram S et al. 3D-ALMOND-QSAR Models to Predict the Antidepressant Effect of Some Natural Compounds 4. *Briefings in Bioinformatics* 2021 – Badkas A et al. Topological network measures for drug repositioning 5. *Molecules* 2021 – Mashraqui MM et al. Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs | | **20** |  |
| **16** | Topîrceanu A, **Udrescu L**, Udrescu M, Mihăicuță S, *Gender Phenotyping of Patients with Obstructive Sleep Apnea Syndrome Using a Network Science Approach,* Journal of Clinical Medicine 2020, Vol. 9(12), pag. 4025 – citat în:   1. *JMIR Medical Informatics* 2021 - Ferreira-Santos D, Rodrigues PP. Enhancing Obstructive Sleep Apnea Diagnosis With Screening Through Disease Phenotypes: Algorithm Development and Validation 2. *Medicina-Lithuania* 2021 – Charciunaite, K et al. Evaluation of Obstructive Sleep Apnea Phenotypes Treatment Effectiveness 3. *Scientific Reports 2021* – Zhou XB et al. Gender differences of clinical and polysomnographic findings with obstructive sleep apnea syndrome | | **12** |  |
| **17** | Rotaru LT, Varut R-M, Amzoiu E, Mormoe M, Nicolaescu O, Amzoiu MO, **Udrescu L**,*Determination of the Antioxidant Capacity of Tragopogon Pratensis Species and Testing Their Pancreatic and Hepatic Regenerative Activity*, Pharmaceutical Chemistry Journal 2020, Vol. 53(10), pag. 964–970 – citat în:   1. *European Journal of Integrative Medicine* 2021 – Dehimat A et al. Cytotoxicity and antioxidant activities of leaf extracts of Varthemia sericea (Batt. et Trab.) Diels 2. *Journal of Science and Arts* 2020 – Ciobanu D et al. Theoretical Docking Studies of Anesthetic Drugs Interactions Used in Emergency Departments 3. *Journal of Science and Arts* 2020 – Florescu C et al. Correlation of Polyphenolic Compounds Structural Properties with Their Antioxidant Capacity | | **12** |  |
| **18** | Udrescu M, **Udrescu L.** A drug repurposing method based on drug-drug interaction networks and using energy model layouts. *Computational Methods for Drug Repurposing*, Part of the *Methods in Molecular Biology* book series, volume 1903, Humana Press, New York, NY, 2019; 185-201 – citat în:   1. *Pharmaceutics* 2021 – Avram S et al. 3D-ALMOND-QSAR Models to Predict the Antidepressant Effect of Some Natural Compounds 2. *European Physical Journal-Special Topics* 2021 – Gouvea AMMM et al. Force-directed algorithms as a tool to support community detection 3. *Journal of Biomolecular Structure & Dynamics* 2020 – Satish Kumar K et al. A systematic computational analysis of human matrix metalloproteinase 13 (MMP-13) crystal structures and structure-based identification of prospective drug candidates as MMP-13 inhibitors repurposable for osteoarthritis 4. *Pharmaceutics* 2020 – Udrescu L. et al. Uncovering new drug properties in target-based drug–drug similarity networks 5. *Journal of Computer-Aided Molecular Design* 2019 - Cardoso-Silva J, et al. Network-based piecewise linear regression for QSAR modelling | | **20** |  |
| **19** | **Udrescu L**, Fuliaş A, Ledeţi I, Vlase G, Barvinschi P, Kurunczi L, Sbârcea L, *Host-guest System of Zofenopril and Randomly Methylated β-cyclodextrin*, Revista de Chimie 2015, Vol. 66(1), pag. 17-20 – citat în:   1. *Journal of Thermal Analysis and Calorimetry* 2020 – Tanase IM et al. Compatibility studies with pharmaceutical excipients for aripiprazole-heptakis (2,6-di-O-methyl)-beta-cyclodextrin supramolecular adduct 2. *Journal of Thermal Analysis and Calorimetry* 2020 – Circioban D et al. Preparation, physicochemical characterization and biological activity evaluation of some inclusion complexes containing artesunate 3. *Journal of Thermal Analysis and Calorimetry* 2016 – Sbarcea L. et al. beta-Cyclodextrin inclusion complexes of lisinopril and zofenopril | | **12** |  |
| **20** | Suciu L, Cristescu C, Topîrceanu A, **Udrescu L**, Udrescu M, Buda V, Tomescu MC, Evaluation of patients diagnosed with essential arterial hypertension through network analysis, Irish Journal of Medical Science 2016, Vol. 185(2), pag. 443-451 – citat în:   1. Scientific Reports 2016 – Udrescu L et al. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing | | **4** |  |
| **21** | Pleava R, Gaita D, Ardelean C, Frent S, Udrescu M, Udrescu L, Dan R, Reisz D, Mihaicuta S. *Obesity in association with Sleep Apnea Syndrome as predictor for coronary-vascular comorbidities*. Pneumologia, 65(1), pp.14-18 – citat în:   1. *Plos One* 2017 – Sesmilo G et al. Prevalence of acromegaly in patients with symptoms of sleep apnea 2. *Neurological Research* 2017 – Z Xie et al. A review of sleep disorders and melatonin 3. *Current Opinion in Psychiatry* 2016 – T. Croenlein. Insomnia and obesity | | **12** |  |
|  |  | | **708** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **IV.a.2.** | **Subcriteriu**  **Citări în tratate / monografii internaționale** | **Puncte/unitate**  **4** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Udrescu L,** Sbârcea L, Topîrceanu A, Iovanovici A, Kurunczi L, Bogdan P, Udrescu M, *Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing*, Scientific Reports 2016, 6:32745 – citat în   1. Sanjel P, Matta J. Inferred Networks and the Social Determinants of Health. În: Benito R.M., Cherifi C., Cherifi H., Moro E., Rocha L.M., Sales-Pardo M. (Editori) Complex Networks & Their Applications X. Complex Networks 2021. Studies in Computational Intelligence, vol 1016. Springer, Cham. <https://doi.org/10.1007/978-3-030-93413-2_58>, 2022 2. Zheng S. et al. *A Computational Bipartite Graph-Based Drug Repurposing Method*. In Computational Methods for Drug Repurposing, Vanhaelen, Q (Editor), Humana Press INC, USA, 2019 3. Udrescu M., Udrescu L. *A Drug Repurposing Method Based on Drug-Drug Interaction Networks and Using Energy Model Layouts*. În Computational Methods for Drug Repurposing, Vanhaelen, Q (Editor), Humana Press INC, USA, 2019 4. Udrescu M, Lihu A. Agreeing to disagree: synergies between particle swarm ptimization and complex networks. În Swarm Intelligence, Vol 1: Principles, Current Algorithms and Methods, Tan Y (Editor), NST Engineering Tech-IET, Michael Faraday House, England, 2018 5. Udrescu L, Sbarcea L. The new tale of some old drugs. În Proceedings of the Romanian National Congress of Pharmacy, 17th Edition , pp.234-240. Draganescu D, Arsene A (Editori), Filodiritto Publisher, Italia, 2018 6. Xu JL et al. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies. În Biocomputing 2018 Proceedings of the Pacific Symposium, Russ B Altman, A Keith Dunker (Editori) <https://doi.org/10.1142/9789813235533_0009> 7. Gare S et al. Dimension reduction and clustering of single cell calcium spiking: Comparison of t-SNE and UMAP. Conference Proceedings 2021 National Conference on Communications, Virtual, Kanpur, 27 July 2021 - 30 July 2021, Elsevier B.V, 2021, DOI 10.1109/NCC52529.2021.9530128 8. Ali SA, Batista-Navarro R. Clustering Cancer Drugs According to their Mechanisms of Action. În 10th International Conference on Semantic Web Applications and Tools for Health Care and Life Sciences, Splendiani A., Marshall M.S. (Editori), CEUR-WS, 2017 | | **32** |  |
| **2** | Mihăicuță Ș, Udrescu M, Topîrceanu A, **Udrescu L**,*Network science meets respiratory medicine for OSAS phenotyping and severity prediction*, PeerJ 2017, 5:e3289 – citat în:   1. Udrescu L, Sbarcea L. The new tale of some old drugs. În Proceedings of the Romanian National Congress of Pharmacy, 17th Edition , pp.234-240. Draganescu D, Arsene A (Editori), Filodiritto Publisher, Italia, 2018 2. National Guideline Centre (UK). (1) Diagnostic tests for OSAHS, OHS and COPD–OSAHS overlap syndrome, (2) Assessment tools for people with suspected OSAHS, OHS or COPD–OSAHS overlap syndrome Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s: Evidence review D. London: National Institute for Health and Care Excellence (NICE); 2021 Aug. (NICE Guideline, No. 202), ISBN-13: 978-1-4731-4229-9, Londra 2021 | | **8** |  |
| **3** | Sbârcea L, **Udrescu L**, Ledeţi I, Szabadai Z, Fuliaş A, Sbârcea C, β-Cyclodextrin inclusion complexes of lisinopril and zofenopril, Journal of Thermal Analysis and Calorimetry 2016, Vol. 123(3), pag. 2377-2390 – citat în:   1. Hadaruga NG et al. Thermal Analyses of Cyclodextrin Complexes. În Cyclodextrin Fundamentals, Reactivity and Analysis. Fourmentin S, Crini G, Lichtfouse E (Editori), Springer International Publishing AG, Elveția, 2018 | | **4** |  |
| **4** | Sbârcea L, Ledeţi I, Drăgan L, Kurunczi L, Fuliaş A, **Udrescu L**,*Fosinopril sodium–hydroxypropyl-*β*-cyclodextrin inclusion complex: Thermal decomposition kinetics and compatibility studies*, Journal of Thermal Analysis and Calorimetry 2015, Vol. 120(1), pag. 981-990 – citat în:   1. Hadaruga NG et al. Thermal Analyses of Cyclodextrin Complexes. În Cyclodextrin Fundamentals, Reactivity and Analysis. Fourmentin S, Crini G, Lichtfouse E (Editori), Springer International Publishing AG, Elveția, 2018 | | **4** |  |
| **5** | Topirceanu A, Udrescu A, **Udrescu L**, Ardelean C, Dan R, Reisz D, Mihaicuta S, *SAS score: Targeting high-specificity for efficient population-wide monitoring of obstructive sleep apnea*, PLoS ONE 2018, 13(9): e0202042 citat în:   1. Topirceanu A. Immunization using a heterogeneous geo-spatial population model: A qualitative perspective on COVID-19 vaccination strategies. În Knowledge-Based And Intelligent Information & Engineering Systems-KSE 2021, Watrobski J, Salabun W (Editori), Elsevier Science BV, Amsterdam, Olanda | | **4** |  |
| **6** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, *Thin-Layer Chromatography Analysis for Cyclodextrins Inclusions Complexes of Fosinopril and Zofenopril*, Farmacia 2010, 58(4), pag. 478–484 – citat în:   1. Lenik J. Chemical application of cyclodextrins in potentiometry: Review. În Cyclodextrins: Synthesis, Chemical Applications and Role in Drug Delivery, Nova Science Publishers, Ramirez FG (Editor), 2015 2. D Agbaba, K Nikolic. TLC of Antihypertensives and Antihypotensive drugs. În Thin Layer Chromatography in Drug Analysis, Lukasz Komsta, Monika Waksmundzka-Hajnos, Joseph Sherma (Editori), CRC Press, 2014 | | **8** |  |
|  |  | | **60** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **IV.a.3.** | **Subcriteriu**  **Citări în reviste internaționale necotate ISI** | **Puncte/unitate**  **1** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | **Udrescu L,** Sbârcea L, Topîrceanu A, Iovanovici A, Kurunczi L, Bogdan P, Udrescu M, *Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing*, Scientific Reports 2016, 6:32745 – citat în   1. *Journal of International Pharmaceutical Research* 2017 – Liu S et al. Informatics related to orphan drug research and discovery: Research advances 2. *Current Opinion in Systems Biology* 2017 – Weinstein ZB, et al. Prediction of synergistic drug combinations. | | **2** |  |
| **2** | **Udrescu L,** Sbârcea L, Fuliaş A, Ledeţi I, Vlase G, Barvinschi P, Kurunczi L, *Physicochemical Analysis and Molecular Modeling of the Fosinopril β-Cyclodextrin Inclusion Complex*, Journal of Spectroscopy 2014, Vol. (2014):748468 – citat în:   1. *Current Drug Discovery Technologies* 2019 – Kaur T et al. Molecular docking in formulation and development 2. *Journal of Chemistry and Chemical Sciences* 2015 – Sasikala M et al. Quantitative Determination of Drugs by Using Cerium (IV) and Indigocaramine Couple: A Spectrophotometric Study 3. *International Journal of Pharmaceutical Sciences and Research* 2015 – Desai C, Prabhakar B. Oral Disintegrating Tablets of Cilostazol-HP-[Beta]-CD Inclusion Complex | | **3** |  |
| **3** | **Udrescu L**, Bogdan P, Chiș A, Sîrbu I-O, Topîrceanu A, Văruț R-M, Udrescu M, *Uncovering new drug properties in target-based drug-drug similarity networks*, Pharmaceutics 2020, Vol. 12(9), pag. 879 – citat în:   1. *Veterinary Sciences* 2022 - Dong, Z., et al. Integrating Network Pharmacology and Molecular Docking to Analyse the Potential Mechanism of action of Macleaya cordata (Willd.) R. Br. in the Treatment of Bovine Hoof Disease 2. *Pharmacology and Therapeutics* 2021 – Cerne R et al. GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors | | **2** |  |
| **4** | Sbârcea L, Ledeţi A, **Udrescu L**, Văruţ R-M, Barvinschi P, Vlase G, Ledeţi I, *Betulonic acid-cyclodextrins inclusion complexes*, [Journal of Thermal Analysis and Calorimetry](https://link.springer.com/journal/10973) 2019, Vol. 138, pag. 2787-2797 – citat în:   1. *International Journal of Molecular Sciences* 2022 - Prodea A et al. The Role of Cyclodextrins in the Design and Development of Triterpene-Based Therapeutic Agents 2. *Revista de Chimie* 2020 – Iftode A et al. Fluconazole-beta-cyclodextrin inclusion complexes. Preparation and characterization in solid state 3. *Journal of Thermal Analysis and Calorimetry* 2019 – R. Oliva et al. Encapsulating properties of sulfobutylether-β-cyclodextrin toward a thrombin-derived antimicrobial peptide | | **3** |  |
| **5** | Sbârcea L, **Udrescu L**, Ledeţi I, Szabadai Z, Fuliaş A, Sbârcea C, β-Cyclodextrin inclusion complexes of lisinopril and zofenopril, Journal of Thermal Analysis and Calorimetry 2016, Vol. 123(3), pag. 2377-2390 – citat în:   1. *Journal of Polymer Research* 2020 – Alizadeh N., Malakzadeh S. Changes in chemical stability and bioactivities of curcumin by forming inclusion complexes of beta- and Gama-cyclodextrins 2. *Journal of Inclusion Phenomena and Macrocyclic Chemistry 2018 -* Malakzadeh S, Alizadeh N. Spectroscopic study and antioxidant activity of the inclusion complexes of cyclodextrins and amlodipine besylate drug 3. *Eurasian Journal of Analytical Chemistry* 2018 - Canbay HS, Doğantürk M. Application of differential scanning calorimetry and Fourier transform infrared spectroscopy to the study of metoprolol-excipient and lisinopril-excipient compatibility | | **3** |  |
| **6** | Sbârcea L, Ledeţi I, Drăgan L, Kurunczi L, Fuliaş A, **Udrescu L**,Fosinopril sodium–hydroxypropyl-β-cyclodextrin inclusion complex: Thermal decomposition kinetics and compatibility studies, Journal of Thermal Analysis and Calorimetry 2015, Vol. 120(1), pag. 981-990 – citat în:   1. *Chemistry and Industry of Forest Products* 2016 – Dong SH et al. Preparation and water solubility of betulinic acid/diethylenetriamine-β-cyclodextrin complex | | **1** |  |
| **7** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, Fosinopril-cyclodextrin inclusion complexes: phase solubility and physicochemical analysis, Pharmazie 2011, Vol. 66(8), pag. 584-589 – citat în:   1. *Turkish Journal of Pharmaceutical Sciences* 2021 - Erdoğar, N. Development of oral tablet formulation containing erlotinib: Randomly methylated-β-cyclodextrin inclusion complex using direct compression method 2. *American Pharmaceutical Revi*ew 2012 - Caira, M.R. Thermal analysis in the characterization of pharmaceutically relevant supramolecular systems 3. *International Journal of Chemical and Analytical Science* 2012 - Sushama Vaishnav-Hota et al. Differential Thermal Analysis of Quercetin-Gamma-Cyclodextrin Inclusion Complex | | **3** |  |
| **8** | Topirceanu A, Udrescu A, **Udrescu L**, Ardelean C, Dan R, Reisz D, Mihaicuta S, *SAS score: Targeting high-specificity for efficient population-wide monitoring of obstructive sleep apnea*, PLoS ONE 2018, 13(9): e0202042 – citat în:   1. *Auris Nasus Larynx* 2021 – Sun X et al. The influence of sex on anthropometric methods and four scales for screening obstructive sleep apnea 2. *Peumologia* 2019 – Ardelean C et al. Risk for stroke and chronic kidney disease in patients with sleep apnea syndrome and heart failure with different ejection fractions | | **2** |  |
| **9** | **Udrescu L**, Sbârcea L, Fuliaş A, Ledeţi I, Vlase G, Barvinschi P, Kurunczi L, *Physicochemical characterization of zofenopril inclusion complex with hydroxypropyl-β-cyclodextrin*, Journal of the Serbian Chemical Society 2015, Vol. 80(4), pag. 485-497 – citat în:   1. *Dhaka University Journal of Pharmaceutical Sciences* 2018 – Aher SV, Pore YV. Physicochemical characterization of febuxostat microcomplexes with parent and modified cyclodextrins | | **1** |  |
| **10** | Rotaru LT, Varut R-M, Amzoiu E, Mormoe M, Nicolaescu O, Amzoiu MO, **Udrescu L**,*Determination of the Antioxidant Capacity of Tragopogon Pratensis Species and Testing Their Pancreatic and Hepatic Regenerative Activity*, Pharmaceutical Chemistry Journal 2020, Vol. 53(10), pag. 964–970 – citat în:   1. *Jordan Journal of Biological Sciences* 2021 – D Abdelouahab. In vitro antioxidant and inhibitory potential of leaf extracts of Varthemia sericea against key enzymes linked to type 2 diabetes | | **1** |  |
| **11** | Sbârcea L, **Udrescu L**, Drăgan L, Trandafirescu C, Bojiță M, Validated UV Spectrofotometric Method For Quantification of Zofenopril in Pharmaceutical Formulations, Revista de Chimie 2012, Vol. 63(6), pag. 562-564 – citat în:   1. *Mediterranean Journal of Chemistry* 2015 – Mabrouk Bouaissi WB, Hmida NB. Development and validation of HPLC method to quantify zofenopril in tablet 2. *Spectrochimica Acta Part A-Molecular and Biomolecular Spectroscopy* 2015 - Stolarczyk, M et al. Derivative spectrophotometric method for simultaneous determination of zofenopril and fluvastatin in mixtures and pharmaceutical dosage forms | | **2** |  |
| **12** | Sbârcea L, **Udrescu L**,Drăgan L, Trandafirescu C, Szabadai Z, Bojiţă M, *Spectrophotometric method for lisinopril determination using ninhydrin*, Farmacia 2014, Vol. 62(1), pag. 107-118 – citat în:   1. *Pharmacia* 2022 - Shulyak N et al. ﻿ Study of the dissolution kinetics of drugs in solid dosage form with lisinopril and atorvastatin and intestinal permeability to assess their equivalence in vitro. | | **1** |  |
| **13** | Suciu L, Cristescu C, Topîrceanu A, **Udrescu L**, Udrescu M, Buda V, Tomescu MC, Evaluation of patients diagnosed with essential arterial hypertension through network analysis, Irish Journal of Medical Science 2016, Vol. 185(2), pag. 443-451 – citat în:   1. *Revista Digital de Postgrado* 2021 – Lárez, C., et al. Caracterización de los pacientes con hipertensión arterial esencial y diabetes mellitus tipo 2 de la consulta externa de un servicio de medicina interna. | | **1** |  |
| **14** | Pleava R, Gaita D, Ardelean C, Frent S, Udrescu M, **Udrescu L**, Dan R, Reisz D, Mihaicuta S. Obesity in association with Sleep Apnea Syndrome as predictor for coronary-vascular comorbidities.   1. *Peumologia* 2019 – Ardelean C et al. Risk for stroke and chronic kidney disease in patients with sleep apnea syndrome and heart failure with different ejection fractions 2. *Peumologia* 2019 – Ardelean C et al. Sleep apnea syndrome and heart failure—mechanisms and consequences 3. *Revista Chilena de Enfermedades Respiratorias* 2017 – Carillo J et al. Prevalencia de riesgo de apnea obstructiva del sueño en población adulta chilena | | **3** |  |
| **15** | Mihăicuță Ș, Udrescu M, Topîrceanu A, **Udrescu L**,*Network science meets respiratory medicine for OSAS phenotyping and severity prediction*, PeerJ 2017, 5:e3289 – citat în:   1. *Peumologia* 2019 – Ardelean C et al. Risk for stroke and chronic kidney disease in patients with sleep apnea syndrome and heart failure with different ejection fractions 2. *Archivos de bronconeumología* 2020 – Silveira M.G., Lloberes P., 2020. Análisis de clúster para identificar fenotipos de síndrome de apneas-hipopneas del sueño:¿ hacia dónde vamos? | | **2** |  |
|  |  | | **30** |  |

**IV.b.Coordonarea de structuri profesionale științifice internaționale**

\*

**IV.c. Coordonare de structuri profesionale științifice naționale**

\*

**IV.d. Calitatea de membru în colective editoriale de prestigiu**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **IV.d.1.** | **Subcriteriu**  **Editor al unei reviste cotate ISI** | **Puncte/unitate**  **40** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Guest editor Pharmaceutics, special issue "In Silico Strategies for Prospective Drug Repositionings"<https://www.mdpi.com/journal/pharmaceutics/special_issues/drug_reposition> | | **40** |  |
|  |  | | **40** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **IV.d2.** | **Subcriteriu**  **Membru în comitetul redacțional al unei reviste cotate ISI** | **Puncte/unitate**  **20** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Pharmaceutics (Q1, IF 6.321) - Topical Advisory Panel | | **20** |  |
|  |  | | **20** |  |

\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.**  **IV.d.3.** | **Subcriteriu**  **Peer-reviewer al unei reviste cotate ISI** | **Puncte/unitate**  **5** | **Subtotal autoevaluare** | **Subtotal comisie** |
| **1.** | Journal of Inclusion Phenomena and Macrocyclic Chemistry, Springer – 7 | | **35** |  |
| **2** | Molecules, MDPI – 3 | | **15** |  |
| **3** | Pharmaceuticals, MDPI – 2 | | **10** |  |
| **4** | Pharmaceutics, MDPI – 1 | | **5** |  |
| **5** | Plants, MDPI – 1 | | **5** |  |
| **6** | Journal of Macromolecular Science, Part A: Pure and Applied Chemistry, Taylor & Francis – 1 | | **5** |  |
| **7** | Drug Development and Industrial Pharmacy, Taylor & Francis – 1 | | **5** |  |
| **8** | Journal of Materials Chemistry B, The Royal Society of Chemistry – 1 | | **5** |  |
| **9** | ACS Omega, The American Chemical Society Publications – 1 | | **5** |  |
| **10** | Molecular Pharmaceutics, The American Chemical Society Publications – 1 | | **5** |  |
| **11** | Industrial & Engineering Chemistry Research, The American Chemical Society Publications – 1 | | **5** |  |
|  |  | | **100** |  |

\*

**IV.e. Calitatea de membru în structuri de cercetare dezvoltare naționale**

**\***

**IV.f. Recunoaștere profesională**

\*

**PUNCTAJUL CUMULAT OBŢINUT**

**CRITERIUL I - ACTIVITATEA DIDACTICĂ**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.** | **Direcţia** | **Subcriteriu** | **Autoevaluare** | **Punctaj comisie** |
| **I.a.** | **Elaborare materiale didactice** |  |  |  |
|  |  | **I.a.1.** |  |  |
|  |  | **I.a.2.** | **20** |  |
|  |  | **I.a.3.** | **6** |  |
|  |  | **I.a.4.** |  |  |
|  |  | **I.a.5.** |  |  |
|  |  | **I.a.6.** | **5** |  |
|  |  | **I.a.7.** | **20** |  |
| **I.b.** | **Activitatea extracuriculară cu studenţii/rezidenţii** |  |  |  |
|  |  | **I.b.1.** |  |  |
|  |  | **I.b.2.** |  |  |
|  |  | **I.b.3.** |  |  |
|  |  | **I.b.4.** |  |  |
|  |  | **I.b.5.** | **3** |  |
| **I.c.** | **Voluntariat (Masterat,cursuri ECM)** |  |  |  |
|  |  | **I.c.1.** |  |  |
|  |  | **I.c.2.** |  |  |
|  |  | **I.c.3.** | **12** |  |
| **I.d.** | **Lucrări de licenţă / disertaţie îndrumate** |  |  |  |
|  |  | **I.d.1.** | **122** |  |
|  |  | **TOTAL** | **188** |  |

**CRITERIUL 2- ACTIVITATEA DE CERCETARE ŞTIINŢIFICĂ**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.** | **Direcţia** | **Subcriteriu** | **Autoevaluare** | **Punctaj comisie** |
| **II.a.** | **Grant de cercetare obținut prin competiție** |  |  |  |
|  |  | **II.a.1.** |  |  |
|  |  | **II.a.2.** |  |  |
|  |  | **II.a.3.** | **30** |  |
|  |  | **II.a.4.** |  |  |
|  |  | **II.a.5.** | **20** |  |
|  |  | **II.a.6.** |  |  |
|  |  | **II.a.7.** |  |  |
|  |  | **II.a.8.** | **3** |  |
| **II.b.** | **Grant de tip workshop obținut prin competiție** |  |  |  |
|  |  | **II.b.1.** |  |  |
|  |  | **II.b.2.** |  |  |
| **II.c.** | **Grant de mobilitate obținut prin competiție**: |  |  |  |
|  |  | **I.c.1.** | **4** |  |
|  |  | **I.c.2.** |  |  |
|  |  | **TOTAL** | **57** |  |

**CRITERIUL 3 - ACTIVITATEA ȘTIINȚIFICĂ**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.** | **Direcţia** | **Subcriteriu** | **Autoevaluare** | **Punctaj comisie** |
| **III.a.** | **Articole publicate în extenso în reviste de circulație internațională recunoscute** |  |  |  |
|  |  | **III.a.1.** | **75** |  |
|  |  | **III.a.2.** | **170** |  |
|  |  | **III.a.3.** | **5** |  |
|  |  | **III.a.4.** |  |  |
|  |  | **III.a.5.** |  |  |
|  |  | **III.a.6.** |  |  |
| **III.b.** | **Articole publicate în rezumat în reviste de circulație internaționale recunoscute** |  |  |  |
|  |  | **III.b.1.** | **20** |  |
|  |  | **III.b.2.** | **27** |  |
|  |  | **III.b.3.** |  |  |
|  |  | **III.b.4.** |  |  |
| **III.c.** | **Articole publicate în extenso în reviste naționale recunoscute.** |  |  |  |
|  |  | **III.c.1.** |  |  |
|  |  | **III.c.2.** |  |  |
|  |  | **III.c.3.** | **5** |  |
|  |  | **III.c.4.** | **15** |  |
|  |  | **III.c.5.** |  |  |
|  |  | **III.c.6.** |  |  |
| **III.d.** | **Monografii sau tratate publicate** |  |  |  |
|  |  | **III.d.1.** |  |  |
|  |  | **III.d.2.** |  |  |
|  |  | **III.d.3.** | **10** |  |
|  |  | **III.d.4.** |  |  |
|  |  | **III.d.5.** |  |  |
|  |  | **III.d.6.** |  |  |
|  |  | **III.d.7.** |  |  |
|  |  | **III.d.8.** |  |  |
|  |  | **III.d.9.** |  |  |
| **III.e.** | **Brevete, invenții, patente** |  |  |  |
|  |  | **III.e.1.** |  |  |
|  |  | **III.e.2.** |  |  |
| **III.f.** | **Lucrării științifice premiate** |  |  |  |
|  |  | **III.f.1.** |  |  |
|  |  | **III.f.2** | **35** |  |
| **III.g.** | **Participare la manifestări științifice internaționale** |  |  |  |
|  |  | **III.g.1.** |  |  |
|  |  | **III.g.2.** | **12** |  |
|  |  | **III.g.3.** |  |  |
|  |  | **III.g.4.** | **2** |  |
| **III.h.** | **Participare la manifestări științifice naţionale cu participare internațională** |  |  |  |
|  |  | **III.h.1.** |  |  |
|  |  | **III.h.2.** |  |  |
|  |  | **III.h.3.** |  |  |
|  |  | **III.h.4.** |  |  |
| **III.i.** | **Participare la manifestări științifice naționale** |  |  |  |
|  |  | **III.i.1.** |  |  |
|  |  | **III.i.2.** | **2** |  |
|  |  | **III.i.3.** | **1** |  |
|  |  | **III.i.4.** |  |  |
|  |  | **TOTAL** | **379** |  |

**CRITERIUL 4 - PRESTIGIUL PROFESIONAL**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.** | **Direcţia** | **Subcriteriu** | **Autoevaluare** | **Punctaj comisie** |
| **IV.a.** | **Citare de lucrări în sistemul ISI ( se scrie și numele revistei/tratate/monografii)** |  |  |  |
|  |  | **IV.a.1.** | **708** |  |
|  |  | **IV.a.2.** | **60** |  |
|  |  | **IV.a.3.** | **30** |  |
| **IVb.** | **Coordonarea de structuri profesionale științifice internaționale** |  |  |  |
|  |  | **IV.b.1.** |  |  |
|  |  | **IV.b.2.** |  |  |
|  |  | **IV.b.3.** |  |  |
| **IV.c.** | **Coordonare de structuri profesionale științifice naționale** |  |  |  |
|  |  | **IV.c.1.** |  |  |
|  |  | **IV.c.2.** |  |  |
|  |  | **IV.c.3.** |  |  |
| **IV.d.** | **Calitatea de membru în colective editoriale de prestigiu** |  |  |  |
|  |  | **IV.d.1.** | **40** |  |
|  |  | **IV.d.2.** | **20** |  |
|  |  | **IV.d.3.** | **100** |  |
|  |  | **IV.d.4.** |  |  |
|  |  | **IV.d.5.** |  |  |
|  |  | **IV.d.6.** |  |  |
| **IV.e.** | **Calitatea de membru în structuri de cercetare dezvoltare naționale** |  |  |  |
|  |  | **IV.e.1.** |  |  |
|  |  | **IV.e.2.** |  |  |
|  |  | **IV.e.3.** |  |  |
|  |  | **IV.e.4.** |  |  |
| **IV.f.** | **Recunoaștere profesională** |  |  |  |
|  |  | **IV.f.1.** |  |  |
|  |  | **IV.f.2** |  |  |
|  |  | **IV.f.3.** |  |  |
|  |  | **IV.f.4.** |  |  |
|  |  | **IV.f.5.** |  |  |
|  |  | **IV.f.6.** |  |  |
|  |  | **IV.f.7.** |  |  |
|  |  | **IV.f.8.** |  |  |
|  |  | **TOTAL** | **958** |  |

**PUNCTAJ TOTAL**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr.** | **Activitatea** | **Criteriul** | **Autoevaluare** | **Punctaj comisie** |
| **1.** | **ACTIVITATEA DIDACTICĂ** | **Criteriul 1** | **188** |  |
| **2.** | **ACTIVITATEA DE CERCETARE ŞTIINŢIFICĂ** | **Criteriul 2** | **57** |  |
| **3.** | **ACTIVITATEA ȘTIINȚIFICĂ** | **Criteriul 3** | **379** |  |
| **4.** | **PRESTIGIUL PROFESIONAL** | **Criteriul 4** | **958** |  |
|  |  | **TOTAL** | **1582** |  |

|  |  |  |
| --- | --- | --- |
| **Candidat:** | **Preşedinte Comisie:** |  |
| NUME Udrescu-Milosav PRENUME Lucreția Paula |  | Semnătura |
| Semnătura \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |  |
|  | **Membrii Comisiei:** |  |
|  |  | Semnătura |
|  |  | Semnătura |
|  |  | Semnătura |
|  |  | Semnătura |
|  |  |  |
|  |  |  |